Stryker (NYSE:SYK) Given New $400.00 Price Target at JPMorgan Chase & Co.

Key Points

• JPMorgan cut its price target on Stryker to $400 (from $445) but kept an "overweight" rating, leaving the stock with roughly a 33% upside from the recent close.
• Stryker missed Q1 estimates (EPS $2.60 vs. $2.98; revenue $6.02B vs. $6.34B) — management blamed a cyber incident; shares fell about 4.8% to ~$300 even as the company maintained FY‑2026 guidance and reported improved cash flow and net income.
• Insider and analyst activity notable: director Ronda E. Stryker sold 250,000 shares for ~$90.7M, while the sell‑side consensus remains a "Moderate Buy" with an average price target near $403.90 despite several target cuts.

Stryker (NYSE:SYK - Get Free Report) had its price target lowered by research analysts at JPMorgan Chase & Co. from $445.00 to $400.00 in a research report issued on Friday,Benzinga reports. The firm presently has an "overweight" rating on the medical technology company's stock. JPMorgan Chase & Co.'s price target indicates a potential upside of 33.34% from the company's previous close.

Several other brokerages have also recently weighed in on SYK. Jefferies Financial Group reaffirmed a "buy" rating and issued a $465.00 price target on shares of Stryker in a research report on Wednesday, March 4th. Truist Financial reduced their price objective on shares of Stryker from $395.00 to $380.00 and set a "hold" rating for the company in a research note on Wednesday, April 15th. The Goldman Sachs Group dropped their target price on Stryker from $403.00 to $357.00 and set a "neutral" rating on the stock in a research report on Thursday, April 9th. Raymond James Financial raised Stryker from a "market perform" rating to an "outperform" rating and set a $418.00 price target for the company in a research report on Tuesday, January 6th. Finally, Robert W. Baird set a $385.00 price objective on Stryker in a research note on Friday. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $403.90.

Stryker Stock Down 4.8%

Shares of SYK traded down $15.15 during midday trading on Friday, reaching $299.98. 2,757,523 shares of the stock were exchanged, compared to its average volume of 2,066,263. The company has a market capitalization of $114.89 billion, a P/E ratio of 35.71, a PEG ratio of 1.84 and a beta of 0.92. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. Stryker has a 52 week low of $299.14 and a 52 week high of $404.87. The company's 50 day moving average is $345.67 and its two-hundred day moving average is $356.95.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $6.34 billion. During the same period last year, the company earned $2.84 earnings per share. The firm's revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, sell-side analysts anticipate that Stryker will post 14.91 earnings per share for the current year.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the company's stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares of the company's stock, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.60% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SYK. Sankala Group LLC purchased a new stake in shares of Stryker during the fourth quarter worth about $26,000. Godfrey Financial Associates Inc. acquired a new stake in Stryker in the 4th quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new stake in Stryker during the 3rd quarter worth approximately $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker during the 4th quarter valued at approximately $27,000. Finally, DJE Kapital AG acquired a new position in Stryker during the 4th quarter valued at approximately $28,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY‑2026 outlook of roughly 8%–9.5% organic sales growth and adjusted EPS guidance of $14.90–$15.10, signaling management confidence in recovery from the cyber incident. Stryker maintains 2026 outlook
• Positive Sentiment: Operational cash flow and net income improved materially in Q1 (cash from operations jumped and net income rose year‑over‑year), which supports the balance sheet and longer‑term investment capacity. Q1 results: cash flow & net income up
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference (May 13), giving investors a near‑term forum for management Q&A and clearer color on cyber recovery and growth drivers. Stryker to participate in BofA conference
• Neutral Sentiment: Several sell‑side firms cut price targets (e.g., Wells Fargo, Needham, BTIG, Truist trimmed targets) but many preserved buy/overweight ratings — that reduces near‑term upside expectations while leaving medium‑term analyst support intact. Analyst price target changes
• Negative Sentiment: Q1 adjusted EPS ($2.60) and revenue ($6.02B) missed consensus, with management attributing shortfalls to a cyber incident that disrupted production, dented margins and slowed growth across key segments. That is the primary driver of the stock weakness today. Stryker Q1 earnings & sales miss on cyber disruption
• Negative Sentiment: News and coverage highlight softer demand in some product lines (spinal/orthopaedics) and margin contraction on an adjusted basis, raising near‑term growth concerns. Reuters: Stryker misses estimates on muted demand
• Negative Sentiment: Large insider and institutional selling activity noted in data aggregators may increase investor caution and amplify short‑term selling pressure. Insider & institutional activity

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.